Edelweiss Balanced Advantage Fund
The scheme will invest in arbitrage opportunities, equity derivative strategies, pure equity investments and the balance in debt and money market instruments.
Growthvine rating: 3/5 — ranked #13 of 37 in category.
Fund basics
| Category | Hybrid: Balanced Advantage |
|---|
| NAV | ₹55.04 (as of 2026-11-13) |
|---|
| AUM | ₹12,880 Cr |
|---|
| Expense ratio | 1.47% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Bharat Lahoti |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 90 days |
|---|
Performance & risk
| 5-year annualised return | 7.64% |
|---|
| Sharpe ratio | 0.4 |
|---|
| Standard deviation | 9.49% |
|---|
| Max drawdown | −16.36% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 112.7% of NIFTY 50 Hybrid Composite Debt 50:50 Index's upside and 102.6% of its downside.
Market cap allocation
| Large cap | 73.9% |
|---|
| Mid cap | 16.2% |
|---|
| Small cap | 9.8% |
|---|
Concentration
| Top 5 holdings | 18.6% |
|---|
| Top 10 holdings | 29.4% |
|---|
| Total holdings | 109 |
|---|
Top holdings
- Clearing Corporation of India Ltd. — 5.5%
- ICICI Bank Ltd. — 4.9%
- HDFC Bank Ltd. — 4.0%
- Reliance Industries Ltd — 3.6%
- Larsen & Toubro Limited — 3.1%
- Infosys Ltd — 3.1%
- TVS Motor Company Ltd. — 2.8%
- State Bank Of India — 2.3%
- ITC Ltd — 2.0%
- 8.05% SUN PHARM SR A R 27-10-31 P 270328 — 1.9%
Top sectors
Not disclosed.
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 4.4% | Q1 (Top) | #4 of 35 |
| 2025 | 7.0% | Q2 | #12 of 34 |
| 2024 | 13.1% | Q2 | #14 of 30 |
| 2023 | 18.8% | Q2 | #11 of 26 |
| 2022 | 2.1% | Q3 | #14 of 21 |